Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 86 от 222

Recruiting Phase 3

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

COVID-19 Infection

This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized for observation or study intervention administration but do not require supplemental oxygen for COVID-19.

Начало: 14.07.2025 Край: 06.05.2027 Възраст: от 18 г.

Argentina, Belgium, Brazil +15 Pfizer NCT07013474

Recruiting Phase 1/2

Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care

Shock, Cardiogenic

The objective of this Phase 1b trial is to evaluate the safety and tolerability of procizumab, a monoclonal antibody under development for the treatment of cardiogenic shock (CS). CS is a life-threatening hypoperfusion of vital organs that frequently results in death. In addition to safety and tolerability, pharmacokinetics and pharmacodynamics of procizumab are evaluated to define the optimum phase 2 dose (P2D) of procizumab.

Начало: 13.07.2025 Край: 01.12.2026 Възраст: 18–80 г.

Armenia, Belgium, Czechia +3 4TEEN4 Pharmaceuticals GmbH NCT06832722

Recruiting

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Chronic Obstructive Pulmonary Disease

The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.

Начало: 11.07.2025 Край: 31.12.2027

China AstraZeneca NCT06862206

Recruiting Phase 1

Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults

Healthy

Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of lobeglitazone administered as M107 Orally Disintegrating Tablet and Duvie tablet in healthy adult participants under fasted and fed conditions.

Начало: 11.07.2025 Край: 02.09.2025 Възраст: 18–55 г. Treatment

Australia Aclipse Two Inc. NCT07056517

Recruiting Phase 2

ERAS Protocols in Breast Conserving Surgery

Breast Cancer Postoperative Recovery

Enhanced Recovery After Surgery (ERAS) protocols have been of increasing interest in the surgical community for decades. The emphasis has been development of protocols to maximize pain control post-operatively without the use of opioids. While this approach has been studied extensively in the oncology surgery literature, little data exists on the utility of ERAS protocols in the setting of breast conserving surgery (BCS), which is a type of surgery to remove breast cancer while saving as much of the breast as possible. The purpose of this study is to determine the utility of implementing ERAS protocols in breast cancer patients undergoing breast conserving surgery. Study participants will be randomized to either ERAS protocol or standard peri-operative care without ERAS. The study will assess the how many opioid prescriptions are given in the first week after surgery and how much pain participants report right after surgery. Investigators will also look at how long participants stay in the recovery room and if medicine for nausea is needed.

Начало: 11.07.2025 Край: 01.02.2029 Възраст: от 19 г.

United States University of Nebraska NCT06938581

Recruiting Phase 3

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Alzheimer Disease

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

Начало: 10.07.2025 Край: 08.12.2028 Възраст: 55–90 г.

Argentina, Brazil, Bulgaria +12 Bristol-Myers Squibb NCT07011732

Recruiting Phase 2

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

Diffuse Intrinsic Pontine Gliomas (DIPG) Progressive DIPG Refractory DIPG Recurrent DIPG +1

This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.

Начало: 10.07.2025 Край: 01.07.2035 Възраст: 12–39 г. Treatment

Australia, Canada, Germany +2 Nationwide Children's Hospital NCT06838676

Recruiting Phase 2

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Metastatic Oral Cavity Carcinoma Recurrent Oral Cavity Carcinoma Stage IVC Lip and Oral Cavity Cancer AJCC v8

This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating oral cavity cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic) among rural Midwest patients. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid and may kill tumor cells. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving the combination of methotrexate, erlotinib, and celecoxib may be feasible, safe, and effective in treating rural Midwest patients with recurrent/metastatic oral cavity cancer.

Начало: 09.07.2025 Край: 30.06.2028 Възраст: от 18 г.

United States Mayo Clinic NCT06997068

Recruiting

ELEVATE-HFpEF Clinical Study

Heart Failure With Preserved Ejection Fraction (HFpEF)

ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).

Начало: 09.07.2025 Край: 01.02.2029 Възраст: от 40 г. Treatment

Australia, Belgium, Canada +8 Medtronic Cardiac Rhythm and Heart Failure NCT06678841

Recruiting

Steps Against the Burden of Parkinson's Disease

Parkinson Disease (PD)

Parkinson's Disease Treadmill Training RCT Summary Parkinson's disease (PD) affects over 10 million people globally. Despite optimal pharmacological treatment, approximately 70% of individuals experience unstable gait and falls, leading to loss of confidence, social isolation, fractures, and frequent hospitalisations. Treadmill training-especially when augmented by mechanical or virtual-reality perturbations-has shown promise in improving gait and reducing fall risk. However, the mechanisms underlying these benefits remain poorly understood, limiting the ability to personalise interventions effectively. This randomised controlled trial (RCT) forms part of the broader Steps Against the Burden of Parkinson's Disease project (CT-IDs: 6ef2e427b002, 6ef2e427b003, 6ef2e427b004), comprising three harmonised but independently conducted RCTs. All sites follow a shared core protocol, allowing for pooled data analysis while preserving site-specific perturbation adaptations. Findings from this trial will be reported both independently and as part of the combined dataset. In this trial, participants with PD will undergo 12 sessions of treadmill training, with or without virtual reality and perturbation-based adaptations. Assessments will be conducted at baseline, post-training, and follow-up. The intervention aims to enhance gait through improved sensorimotor integration and balance control. During the follow-up period, a smartphoneapp "Walking Tall" will be used to encourage continued exercises and long-term retention of training effects. Biomechanical analyses will focus on changes in foot placement control. Neurophysiological outcomes will be examined using EEG and EMG, targeting reductions in beta-band EEG power and enhanced EEG-EMG coherence as markers of improved gait stability. Recognising that laboratory-based improvements may not always translate to daily life, this study will also investigate gait self-efficacy as a potential moderator of transfer. Remote monitoring tools will capture real-world mobility outcomes over a week. Machine learning techniques will be employed to identify factors differentiating those who improve in both settings from those who do not. These insights will inform the development of personalised interventions capable of translating training effects into meaningful real-life outcomes.

Начало: 09.07.2025 Край: 30.11.2026 Възраст: от 18 г. Basic science

Australia The University of New South Wales NCT07057219

Recruiting

Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients

Pneumocystis Immunocompromised Patients

Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients

Начало: 08.07.2025 Край: 08.07.2027 Възраст: от 18 г.

France Assistance Publique - Hôpitaux de Paris NCT06890078

Recruiting

Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors

Stage II Colorectal Cancer AJCC v8 Stage III Colorectal Cancer AJCC v8 Colorectal Carcinoma

This trial evaluates the effects a moderate-to-vigorous exercise intervention has on the bacterial make-up of the gastrointestinal tract (gut microbiota) in survivors of stage II-III colorectal cancer (CRC). Data shows that the gut microbiota composition and function may be drivers of CRC. High levels of exercise are associated with improved CRC prognosis and survival. While data suggests that exercise has the potential to influence gut microbiota composition and function, it is not known whether these effects contribute to improved CRC prognosis. This clinical trial evaluates the effects an exercise intervention has on gut microbiota and how these effects relate to CRC progression and patient-reported outcomes.

Начало: 08.07.2025 Край: 01.07.2027 Възраст: 18–70 г.

United States Fred Hutchinson Cancer Center NCT05930496

Recruiting

Effect of a Liquid Tonic Drink on Post-meal Glucose and Insulin Responses

Overweight or Obese Adults

A randomised, double blinded, placebo-controlled crossover design clinical trial conducted at the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with overweight/ obesity. This study will measure the postprandial glucose and hormone responses to a high-carbohydrate meal with/ without a liquid tonic drink.

Начало: 08.07.2025 Край: 19.12.2025 Възраст: 30–64 г. Basic science

Australia Australian Catholic University NCT07030010

Recruiting Phase 2

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-sensitive Prostate Cancer

This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated

Начало: 07.07.2025 Край: 19.10.2035 Възраст: от 18 г. Treatment

Australia, Brazil, Canada +12 Novartis Pharmaceuticals NCT06991556

Recruiting

Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer

Abdominal Cancer

The aim of this study is to investigate the effect of MRI-guided adaptive stereotactic radiotherapy on local control, survival, and toxicity in the treatment of oligometastatic cancer to the abdomen.

Начало: 07.07.2025 Край: 01.01.2030 Възраст: от 18 г. Treatment

Australia Australasian Gastro-Intestinal Trials Group NCT06604533

Recruiting Phase 2

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

Ulcerative Colitis

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Начало: 07.07.2025 Край: 17.10.2029 Възраст: 18–75 г. Treatment

Australia, China, Czechia +9 Sanofi NCT06975722

Recruiting

Nurturing Outreach for Understanding and Reducing Inpatient Security of Health

Food Insecurity

Food insecurity is the lack of consistent access to the food needed for a healthy life. Food insecurity among families whose child has been hospitalized is a critical problem affecting a large, vulnerable population. The purpose of this study is to identity the most effective ways to help those families with food insecurity.

Начало: 07.07.2025 Край: 01.12.2026

United States Wake Forest University Health Sciences NCT07010289

Recruiting Phase 4

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Relapsing Multiple Sclerosis Primary Progressive Multiple Sclerosis

The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).

Начало: 04.07.2025 Край: 23.04.2027 Възраст: 18–55 г.

China Hoffmann-La Roche NCT07483450

Recruiting Phase 1

A phase I study of [68Ga]Ga-DWJ155 in patients with advanced breast and NSCLC cancers

Advanced breast cancer and advanced NSCLC

Trial status: Authorised

Начало: 03.07.2025 Възраст: от 18 г.

Netherlands Novartis Pharma AG 2024-517746-34-00

Recruiting Phase 1/2

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Castration-Resistant Prostatic Cancer Metastasis

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Participant levels of prostate specific antigen (PSA) during treatment.

Начало: 03.07.2025 Край: 01.04.2031 Възраст: от 18 г. Treatment

Argentina, Australia, Brazil +16 Merck Sharp & Dohme LLC NCT06863272

1 … 84 85 86 87 88 … 222